Table 5.
Clinical course of adjuvant chemotherapy
| FOLFOX (n=203) |
CAPOX (n=10) |
5-FU/LV (n=12) |
Capecitabine (n=15) |
UFT/LV (n=6) |
Total (n=246) |
||||
|---|---|---|---|---|---|---|---|---|---|
| Visit 2 | Dose adjustment | 43 (21.2) | 3 (30) | 0 | 3 (20) | 0 | 49 (19.9) | ||
| Treatment delay | 66 (32.5) | 2 (20) | 1 (8.3) | 3 (20) | 1 (16.7) | 73 (29.7) | |||
| Early stop | 13 (6.4) | 1 (10) | 0 | 0 | 0 | 14 (5.7) | |||
| No. of patients ongoing | 190 | 9 | 12 | 15 | 6 | 232 | |||
| Visit 3 | Dose adjustment | 38 (20) | 1 (11.1) | 0 | 4 (26.7) | 0 | 43 (18.5) | ||
| Treatment delay | 63 (33.2) | 3 (33.3) | 3 (25.3) | 3 (20) | 1 (16.7) | 73 (31.5) | |||
| Early stop | 29 (15.3) | 0 | 1 (8.3) | 2 (13.3) | 0 | 32 (13.8) | |||
| No. of patients completed | 161 | 9 | 11 | 13 | 6 | 200 | |||
Data overlapping was allowed.
FOLFOX: leucovorin, 5-fluorouracil, and oxaliplatin; CAPOX: capecitabine and oxaliplatin; 5-FU/LV: 5-fluorouracil with leucovorin; UFT/LV: uracil-tegafur and leucovorin